Redcliffe Labs, a purpose-driven PAN India diagnostic service provider, has announced the launch of its advanced MPOX testing capabilities, reinforcing its commitment to national health security. This strategic move is a significant step towards bolstering the nation’s preparedness against potential MPOX outbreaks and demonstrates Redcliffe Labs’ continuous dedication to ensuring India’s right to access quality diagnostics.
With its widespread network of 80+ in-house world-class labs, 2000+ collection centers, and presence in 220+ cities, Redcliffe Labs played a crucial role in combating the COVID-19 pandemic across both waves and is once again at the forefront of safeguarding public health.
MPOX, a highly contagious viral disease increasingly recognized for its potential to cause localized outbreaks, poses significant public health risks if not detected and controlled promptly. With several cases reported in Africa, Europe, and parts of Asia, the urgency of this threat necessitates early preparedness and timely intervention to prevent the virus from spreading.
Redcliffe Labs has proactively assured key health authorities, including Noida’s Chief Medical Officer (CMO) and the Indian Council of Medical Research (ICMR), of its readiness to manage the MPOX situation. Being prepared with advanced testing facilities not only ensures the rapid identification and isolation of cases but also guarantees that healthcare providers are fully equipped to handle increased demand. Additionally, it enables timely public communication and education, reducing misinformation and helping manage the community impact.
Aditya Kandoi, CEO of Redcliffe Labs, said, “At Redcliffe Labs, we understand that being fully prepared with advanced diagnostics is the key to successfully managing public health crises. Our commitment to delivering quality diagnostics has been unwavering, and our introduction of MPOX testing reflects our proactive approach to future health challenges. We are ready to work closely with health authorities to ensure the safety and well-being of our community.”
“Mpox, similar to other highly contagious viral infections, demands early detection for timely and effective intervention. Early diagnosis is crucial to preventing complications, limiting the spread of the disease, and safeguarding public health. By ensuring swift identification, we can enhance patient outcomes and protect communities from further outbreaks,” said Dr. Geetanjali Gupta, Director-Technical Operations and Quality Assurance Redcliffe Labs.
Redcliffe Labs aims to enhance national pandemic defense and safeguard public health against MPOX threats through strategic readiness and innovative diagnostic solutions. By leading the charge in diagnostic capabilities, they continue to play a critical role in supporting India’s health infrastructure.